15417786mcr150063t-sup-144999_1_supp_2908391_nlkv5k.png (32.92 kB)
Supplementary figure S1 from Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors
figure
posted on 2023-04-03, 16:26 authored by Lisa Lindström, Bruno O. Villoutreix, Sophie Lehn, Rebecka Hellsten, Elise Nilsson, Enisa Crneta, Roger Olsson, Maria Alvarado-KristenssonSupplementary figure S1. CDA treatment induces a G2/M cell cycle arrest.
History
ARTICLE ABSTRACT
In addition to its cytosolic function, γ-tubulin is a chromatin-associated protein. Reduced levels of nuclear γ-tubulin increase the activity of E2 promoter-binding factors (E2F) and raise the levels of retinoblastoma (RB1) tumor suppressor protein. In tumor cells lacking RB1 expression, decreased γ-tubulin levels induce cell death. Consequently, impairment of the nuclear activity of γ-tubulin has been suggested as a strategy for targeted chemotherapy of RB1-deficient tumors; thus, tubulin inhibitors were tested to identify compounds that interfere with γ-tubulin. Interestingly, citral increased E2F activity but impaired microtubule dynamics while citral analogues, such citral dimethyl acetal (CDA), increased E2F activity without affecting microtubules. The cytotoxic effect of CDA on tumor cells was attenuated by increased expression of either RB1 or γ-tubulin, and increased by reduced levels of either RB1 or γ-tubulin. Mechanistic study, in silico and in vitro, demonstrated that CDA prevents GTP binding to γ-tubulin and suggested that the FDA-approved drug dimethyl fumarate is also a γ-tubulin inhibitor. Finally, in vivo growth of xenograft tumors carrying defects in the RB1 signaling pathway were inhibited by CDA treatment. These results demonstrate that inhibition of γ-tubulin has the potential to specifically target tumor cells and may aid in the design of safer and more efficient chemotherapeutic regimes.Implications: The in vivo antitumorigenic activity of γ-tubulin inhibitors paves the way for the development of a novel broad range targeted anticancer therapy that causes fewer side effects. Mol Cancer Res; 13(7); 1073–82. ©2015 AACR.Usage metrics
Categories
Keywords
Cell CycleControl of cell cycle progressionSignal transduction pathwaysCell SignalingComputational MethodsMolecular modelingDrug Discovery TechnologiesScreening strategies (assays and chemical libraries)Drug TargetsGene RegulationMechanisms of transcriptionOncogenes & Tumor SuppressorsRb and familySmall Molecule AgentsTubulin agents
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC